The Combined Clinical Efficacy and Safety Analysis of Adoptive Immunotherapy with Radiotherapy and Chemotherapy in Non-Small-Cell Lung Cancer: Systematic Review and Meta-Analysis
Objective. To explore the differential efficacy of chemoradiotherapy combined with adoptive immunotherapy and radiochemotherapy alone in patients with non-small-cell lung cancer (NSCLC). Methods. Qualified randomized controlled trial (randomized controlled trial, RCT), or nonrandomized concurrent co...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Applied Bionics and Biomechanics |
| Online Access: | http://dx.doi.org/10.1155/2022/2731744 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849412955843592192 |
|---|---|
| author | Zhiming Fan Honggui He Liqun Chen |
| author_facet | Zhiming Fan Honggui He Liqun Chen |
| author_sort | Zhiming Fan |
| collection | DOAJ |
| description | Objective. To explore the differential efficacy of chemoradiotherapy combined with adoptive immunotherapy and radiochemotherapy alone in patients with non-small-cell lung cancer (NSCLC). Methods. Qualified randomized controlled trial (randomized controlled trial, RCT), or nonrandomized concurrent controlled trial (NRCCT), published in various databases, including PubMed, EMBASE, Chinese journal full-text database, Medline, Cochrane database, and VIP Chinese database, and the Revman5. 0 software performed the data analysis. Results. We found the significantly different curative effect between the experimental and control groups (OR=1.94, 95% CI (1.46, 2.58), P<0.001, I2=0%, Z=4.59), effect of adoptive immunotherapy on the progression of disease (OR=1.80, 95% CI (1.38, 2.35), P<0.001, I2=0%, Z=4.33), adoptive immunotherapy on overall survival (OR=2.19, 95% CI (1.60, 2.99), P<0.001, I2=0%, Z=4.91), and adverse effects of adoptive immunotherapy (OR=1.76, 95% CI (1.25, 2.48), P=0.001, I2=0%, Z=3.26). Conclusion. Adoptive immunotherapy combined with microradiotherapy can decrease the recurrence of NSCLC and improve patient survival, as well as early patients can be benefited more significantly from immunotherapy. |
| format | Article |
| id | doaj-art-6629a88208784af7b8fbcb6c4a0e87ae |
| institution | Kabale University |
| issn | 1754-2103 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Applied Bionics and Biomechanics |
| spelling | doaj-art-6629a88208784af7b8fbcb6c4a0e87ae2025-08-20T03:34:17ZengWileyApplied Bionics and Biomechanics1754-21032022-01-01202210.1155/2022/2731744The Combined Clinical Efficacy and Safety Analysis of Adoptive Immunotherapy with Radiotherapy and Chemotherapy in Non-Small-Cell Lung Cancer: Systematic Review and Meta-AnalysisZhiming Fan0Honggui He1Liqun Chen2Departments of OncologyDepartments of OncologyDepartments of OncologyObjective. To explore the differential efficacy of chemoradiotherapy combined with adoptive immunotherapy and radiochemotherapy alone in patients with non-small-cell lung cancer (NSCLC). Methods. Qualified randomized controlled trial (randomized controlled trial, RCT), or nonrandomized concurrent controlled trial (NRCCT), published in various databases, including PubMed, EMBASE, Chinese journal full-text database, Medline, Cochrane database, and VIP Chinese database, and the Revman5. 0 software performed the data analysis. Results. We found the significantly different curative effect between the experimental and control groups (OR=1.94, 95% CI (1.46, 2.58), P<0.001, I2=0%, Z=4.59), effect of adoptive immunotherapy on the progression of disease (OR=1.80, 95% CI (1.38, 2.35), P<0.001, I2=0%, Z=4.33), adoptive immunotherapy on overall survival (OR=2.19, 95% CI (1.60, 2.99), P<0.001, I2=0%, Z=4.91), and adverse effects of adoptive immunotherapy (OR=1.76, 95% CI (1.25, 2.48), P=0.001, I2=0%, Z=3.26). Conclusion. Adoptive immunotherapy combined with microradiotherapy can decrease the recurrence of NSCLC and improve patient survival, as well as early patients can be benefited more significantly from immunotherapy.http://dx.doi.org/10.1155/2022/2731744 |
| spellingShingle | Zhiming Fan Honggui He Liqun Chen The Combined Clinical Efficacy and Safety Analysis of Adoptive Immunotherapy with Radiotherapy and Chemotherapy in Non-Small-Cell Lung Cancer: Systematic Review and Meta-Analysis Applied Bionics and Biomechanics |
| title | The Combined Clinical Efficacy and Safety Analysis of Adoptive Immunotherapy with Radiotherapy and Chemotherapy in Non-Small-Cell Lung Cancer: Systematic Review and Meta-Analysis |
| title_full | The Combined Clinical Efficacy and Safety Analysis of Adoptive Immunotherapy with Radiotherapy and Chemotherapy in Non-Small-Cell Lung Cancer: Systematic Review and Meta-Analysis |
| title_fullStr | The Combined Clinical Efficacy and Safety Analysis of Adoptive Immunotherapy with Radiotherapy and Chemotherapy in Non-Small-Cell Lung Cancer: Systematic Review and Meta-Analysis |
| title_full_unstemmed | The Combined Clinical Efficacy and Safety Analysis of Adoptive Immunotherapy with Radiotherapy and Chemotherapy in Non-Small-Cell Lung Cancer: Systematic Review and Meta-Analysis |
| title_short | The Combined Clinical Efficacy and Safety Analysis of Adoptive Immunotherapy with Radiotherapy and Chemotherapy in Non-Small-Cell Lung Cancer: Systematic Review and Meta-Analysis |
| title_sort | combined clinical efficacy and safety analysis of adoptive immunotherapy with radiotherapy and chemotherapy in non small cell lung cancer systematic review and meta analysis |
| url | http://dx.doi.org/10.1155/2022/2731744 |
| work_keys_str_mv | AT zhimingfan thecombinedclinicalefficacyandsafetyanalysisofadoptiveimmunotherapywithradiotherapyandchemotherapyinnonsmallcelllungcancersystematicreviewandmetaanalysis AT hongguihe thecombinedclinicalefficacyandsafetyanalysisofadoptiveimmunotherapywithradiotherapyandchemotherapyinnonsmallcelllungcancersystematicreviewandmetaanalysis AT liqunchen thecombinedclinicalefficacyandsafetyanalysisofadoptiveimmunotherapywithradiotherapyandchemotherapyinnonsmallcelllungcancersystematicreviewandmetaanalysis AT zhimingfan combinedclinicalefficacyandsafetyanalysisofadoptiveimmunotherapywithradiotherapyandchemotherapyinnonsmallcelllungcancersystematicreviewandmetaanalysis AT hongguihe combinedclinicalefficacyandsafetyanalysisofadoptiveimmunotherapywithradiotherapyandchemotherapyinnonsmallcelllungcancersystematicreviewandmetaanalysis AT liqunchen combinedclinicalefficacyandsafetyanalysisofadoptiveimmunotherapywithradiotherapyandchemotherapyinnonsmallcelllungcancersystematicreviewandmetaanalysis |